|
Hear It Here First!! Sign Up Today!! IWEB,GETA,BMSN
(M2 PressWIRE Via Acquire Media NewsEdge) Stock Hunter PRESENTS : (OTCBB: IWEB) IceWEB, Inc., (OTCBB: GETA) Genta Incorporated, (OTCBB: BMSN) Bio-Matrix Scientific Group, Inc., (OTCBB: GDTI) Guardian Technologies International, Inc., (OTCBB: BGBR) Big Bear Mining Corp., (OTCBB: VPWI) Viper Powersports, Inc.
www.Stockhunter.us
To sign up for our free Profiles & Alerts :: visit http://www.StockHunter.us
Email us!! Steve@StockHunter.us
------------------------------------------------------------------------------------------------------------------------------------------------------------
(OTCBB: IWEB - IceWEB, Inc.)
LATEST NEWS!!
IceWEB Launches the IceWEB Advantage Finance Program
Program to Provide a Fast and Flexible Finance Program for IceWEB Channel Partners
STERLING, Va., April 20, 2010-- IceWEB(TM), Inc. (OTC Bulletin Board: IWEB), a leading provider of Unified Data Storage and building blocks for cloud storage networks, announced today the launch of the IceWEB Advantage(TM) Finance/Lending program. The IceWEB Advantage Program was custom designed for IceWEB Channel Partners that require fast and flexible funding to win deals. The program gives IceWEB and its partners the ability to bundle multiple items into a single financing package as if they are sold as one order, as long as the order includes IceWEB products.
Program Details include: Unlimited order size Single Source Bundled financing - Channel Partner can fund entire order as long as it includes IceWEB products Short and long-term lease/buyout/technical refresh options (same day approval on all leases under $100k) Government funding for GSA contract awards and contract task orders 90 day flooring policy - same as cash Guaranteed same day purchase order financing - proof of customer P.O. is all that is required Guaranteed same day accounts receivable financing - proof of customer P.O. and valid invoice is all that is required Online Channel Banking - available in 45 days through IceWEB Partner Portal "Easy and accessible funding is the biggest challenge facing the channel today. More often than not it takes creative financial engineering to get a deal shipped and invoiced. Since bank lines are for the most part nonexistent, access to quick and affordable financing is key. Our goal is to make it easy and effortless for IceWEB Channel Partners to do business," stated Mark B. Lucky, IceWEB CFO. "YES WE CAN provide our partners with the financing they need at the time they need it." About IceWEB, Inc.
Headquartered just outside of Washington, D.C., IceWEB manufactures and markets data storage products, network and cloud storage solutions and delivers on-line cloud computing application services. Its customer base includes U.S. government agencies, enterprise companies, and small to medium sized businesses (SMB). For more information, please visit www.IceWEB.com.
------------------------------------------------------------------------------------------------------------------------------------------------------------
(OTCBB: GETA - Genta Incorporated)
LATEST NEWS!!
Genta Presents Initial Clinical Data on Use of Gallium Compounds as Treatment for Serious Infections
-- AACR presentation suggests potential applications in cystic fibrosis, cancer, and sepsis
BERKELEY HEIGHTS, N.J., Apr 20, -- Clinical study in cystic fibrosis to start in May 2010 Genta Incorporated (OTCBB: GETA) today announced the presentation of initial results from the first human use of a gallium-containing compound to treat serious infection. In a patient with cystic fibrosis and a highly resistant lung infection, who has been treated over a 2-year period, high concentrations of gallium were achieved in sputum. Moreover, sputum concentrations were higher than simultaneous concentrations in blood and continued to rise even after treatment had been stopped. Measured concentrations in sputum equaled or exceeded concentrations that have been reported lethal to bacteria in laboratory tests. The data were presented at the annual meeting of the American Association of Cancer Research in Washington, D.C.
Gallium is known to interfere with certain iron-dependent metabolic processes, which can be lethal to single-cell organisms such as bacteria, mycobacteria (e.g., tuberculosis), protozoa (e.g., malaria), and fungi. Infection is the most common cause of death in patients with cystic fibrosis, which are frequently caused by bacteria known as Pseudomonas aeruginosa that have become highly resistant after years of antibiotic therapy. Recent laboratory data have suggested that gallium may kill these bacteria and also augment the activity of standard antibiotics.
In a preliminary clinical test, a patient with cystic fibrosis and extensive lung infection due to highly resistant Pseudomonas was treated with intermittent intravenous (IV) infusions of gallium nitrate (administered as Ganite(R) [gallium nitrate injection]) over a 2-year period. Blood and sputum concentrations were measured during and after two of these infusions.
Sputum gallium concentrations from infected lungs were consistently higher than levels simultaneously obtained in plasma. In the 2 cycles of treatment with pharmacologic monitoring, these concentrations substantially exceeded levels that laboratory tests had previously shown were lethal to resistant Pseudomonas. Moreover, gallium concentrations in sputum continued to rise even after IV therapy was discontinued. Extended treatment with IV gallium nitrate was well-tolerated despite the presence of extensive lung disease and substantial compromise of pulmonary function. Previously deteriorating clinical status due to pulmonary failure was stable over the 2-year period.
"These data show that gallium is preferentially concentrated in sputum of infected lungs," said Dr. Raymond P. Warrell, Jr., Genta's Chief Executive Officer. "High levels were achieved and sustained during short courses of treatment -- an especially promising result that should obviate any need to consider direct inhalation. A new clinical trial to formally evaluate IV gallium nitrate in patients with cystic fibrosis will begin next month. These preliminary data also suggest that our oral gallium-containing compound may be useful for this purpose as chronic therapy." The potential use(s) described in this release are investigational and have not been approved. Genta is exclusively marketing an IV form of gallium nitrate (Ganite(R) [gallium nitrate injection]), which is indicated for treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The Company has also developed proprietary oral formulations of the active ingredient in Ganite(R) that are being evaluated as potential treatments for diseases associated with accelerated bone loss.
The new clinical trial discussed in this release is expected to begin in May 2010 and will enroll patients with cystic fibrosis who will be treated at the University of Washington, Seattle, WA, and the University of Iowa, Iowa City, IA. If initial results are promising, additional trials may be conducted at other medical centers in a larger number of patients. For this trial, Genta has provided cross-reference to its Investigational New Drug (IND) exemption for Ganite(R), and the Company will supply the drug at no cost to patients in the trial. The study is supported by grants from the Orphan Products Division of the Food and Drug Administration (FDA) and the Cystic Fibrosis Foundation. Further background on this work can be accessed at: http://www.jci.org/articles/view/30783/pdf.
About Ganite(R) Ganite(R) is exclusively marketed by Genta and is approved in the U.S. for treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The potential use(s) described in this release are investigational and have not been approved.
About Genta Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genasense(R) is being developed as an agent that may enhance the effectiveness of anticancer therapy. The Company is currently collecting long-term followup data on durable response and overall survival from the recently completed randomized Phase 3 study of Genasense(R) in patients with advanced melanoma (the AGENDA trial). The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Genta has initiated a broad clinical program to evaluate the safety and efficacy of tesetaxel in patients with solid tumors. In the U.S., Genta is exclusively marketing Ganite(R) (gallium nitrate injection), which is indicated for treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The Company has developed proprietary oral formulations of the active ingredient in Ganite(R) that are being evaluated as potential treatments for diseases associated with accelerated bone loss. Ganite(R) and Genasense(R) are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com.
------------------------------------------------------------------------------------------------------------------------------------------------------------
(OTCBB: BMSN - Bio-Matrix Scientific Group, Inc.)
LATEST NEWS!!
Bio-Matrix Scientific Group, Inc. Announces Elimination of $1.1 Million of Debt
SAN DIEGO, CA, Apr 20, 2010 -- Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) today announced the elimination of an additional $1,109,309 in obligations during the quarter ended March 31, 2010. These obligations, including $251, 528 owed on loans made to BMSN by a company controlled by Chairman & CEO Dr. David Koos as well as $304,500 in accrued salaries, were satisfied through the issuance of 17,337,728 shares of common stock. Dr. Koos stated, "I believe the future of Bio-Matrix Scientific Group Inc. is bright. Our majority owned subsidiary, Entest BioMedical, Inc. is making what I believe to be great strides in developing revolutionary new therapies utilizing stem cells." Dr. Koos also stated that "an immunotherapeutic cancer vaccine for the treatment of canine cancer being developed by BMSN's subsidiary in conjunction with Therinject, Inc. has the potential to yield revenue of $6,000,000 by the end of its first year of availability. In addition, the proposed acquisition of Medistem, Inc. by Entest would bring to the consolidated company a portfolio of products covered by 18 families of patent applications. This product portfolio includes Medistem's proprietary Endometrial Regenerative Cell (ERC), a 'universal donor' stem cell derived from the menstrual blood that possesses the ability to differentiate into nine tissue types and produce large quantities of growth factors. My personal belief is that that the current endeavors of the Company will provide value to shareholders, so I'm putting my money where my mouth is." About Bio-Matrix Scientific Group: Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a biotechnology company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories. David Koos serves as Chairman & CEO concurrently for BMSN and ENTB.
------------------------------------------------------------------------------------------------------------------------------------------------------------
(OTCBB: GDTI - Guardian Technologies International, Inc.)
LATEST NEWS!!
Guardian Technologies Receives 1st Automated Tuberculosis Detection System Order From South Africa
HERNDON, VA, Apr 20, 2010 -- Guardian Technologies International, Inc. (OTCBB: GDTI) has received its first order for three fully automated Signature Mapping Tuberculosis Diagnostic (TBDx(TM)) systems for planned shipment at the end of April. The order is in preparation for the final clinical evaluation of the TBDx fully automated detection system that will begin in May 2010.
"Guardian Technologies is extremely proud to deliver to the South African National Health Laboratory Services ("NHLS") the first total tuberculosis diagnostic solution that addresses the dual challenges of detection and slide throughput," states Rich Borrelli, Guardian's Vice President of Healthcare. "Testing of the automated TBDx system to date indicates that it provides a fast, accurate diagnosis at a low cost without requiring clean rooms, cultures or other resource intensive processes. Successful completion of the final clinical evaluation in South Africa will set the stage for the introduction of the fully automated system to other countries faced with large, growing volumes of TB such as India, China, and Russia." The breakthrough TBDx system combines automated digital image analysis software to detect TB in sputum microscopy samples using a fully automated slide handling system capable of continuously processing 200 slides without the need for human intervention. The complete automated system will provide the NHLS with the ability to eliminate tedious and time-consuming diagnostic efforts while more consistently and accurately detecting tuberculosis bacilli and maintaining a low false positive rate.
The final clinical evaluation has two objectives: (i) confirm the initial clinical results obtained in October 2009 utilizing the auto-focus integrated microscope and camera capability, and (ii) measure the operational efficiencies and potential cost-savings of fully automated operations. The measurement of slide analysis throughput is required for NHLS to determine the quantity of required systems and deployment strategy. Post-clinical evaluation, the three TBDx systems will be transitioned to NHLS laboratories most heavily involved in ongoing tuberculosis research.
About Guardian Technologies International: Guardian Technologies uses high-performance imaging technologies and advanced analytics to create integrated information management products and services. Currently, the company offers products and services for use in disease detection and airport security. By automating the processing of large quantities of graphic, numeric, and textual data, Guardian allows organizations to more efficiently detect, extract, analyze or effectively act upon the information. Guardian's solutions are designed to improve the quality and speed of decision-making and enhance organizational productivity and accuracy.
------------------------------------------------------------------------------------------------------------------------------------------------------------
(OTCBB: BGBR - Big Bear Mining Corp.)
LATEST NEWS!!
Big Bear Mining Corp. Announces Addition of New Board Member, Renowned Geologist John Glasscock, of Cowboy Exploration
TEMPE, Ariz., April 20, -- Big Bear Mining (OTCBB: BGBR) is pleased to announce that Mr. John Glasscock has joined the board of directors. Mr. Glasscock is a geologist with over 25 years of experience in the mineral exploration industry including involvement with the startup of four junior mining companies. He is the founder of Cowboy Exploration which for over 15 years has had extensive experience generating and managing projects throughout the Western US, Mexico, and China.
President of Big Bear Mining, Steve Rix states, "Having John on the team is an honor and we take his commitment to Big Bear seriously. We will begin working with John to formulate a plan for our exploration in the Western United States. We are confident that his addition will increase the probability of us fulfilling our mission to find near term producing properties." John's most recent accomplishments include responsibility for the acquisition and exploration of a large uranium property portfolio for Tournigain Energy Ltd. (TSX-V:TVC) and the generation of several gold properties for Crescent Resources Corp. (TSX VENTURE:CRC) in the Rattlesnake Hills, WY. John will not only be active in the identifying and acquisition of new properties and their corresponding work programs. He will also assist Big Bear in its unique JV program presently in development.
About Big Bear Mining Corp.: bigbearmining.com Big Bear Mining Corp. is a US based exploration and development company, focusing on the acquisition and development of Gold and other precious commodity projects which demonstrate high probability for near term production. Big Bear is a fully reporting company quoted on the OTCBB under the symbol BGBR
------------------------------------------------------------------------------------------------------------------------------------------------------------
(OTCBB: VPWI - Viper Powersports, Inc.)
LATEST NEWS!!
Viper Motorcycle Company Will Display Motorcycles With Ilmor Engineering Inc. April 22 Through 25 at Desert Storm 2010 in Lake Havasu City, Arizona
HOPKINS, MN, Apr 20, 2010 Viper Motorcycle Company (OTCBB: VPWI), a wholly owned subsidiary of Viper Powersports Inc., will participate and display product at the 2010 Desert Storm Show and Poker Run at the Nautical Inn Resort in Lake Havasu City, Arizona. This is an annual event bringing together some of the most significant performance boats from across the nation. Ilmor provides high performance marine engines for many of the participants and based on our joint venture also provides the proprietary all billet 152 cubic inch engine for all Viper motorcycles.
Terry Nesbitt, President of Viper, stated, "This is our first effort to co-promote and brand with Ilmor and promises to be an ongoing effort to develop our relationship. We are excited to be invited and hope to bring credibility with our products to such an impressive event." According to Paul Ray, President, Ilmor Engineering Inc., "We have been a supporter and participant in this outstanding event for many years. It provides us the opportunity to support our customers and display our products to a very enthusiastic audience. Viper will co-display with us during the Desert Storm Street-Party Thursday night, and at the Nautical Inn Resort for the rest of the weekend. This style of event offers Viper and Ilmor a perfect chance to raise awareness of our joint venture. The all new Ilmor designed, 152cu-in billet aluminum engine is an industry first offering incredible power, advanced oil/air cooling and superior reliability. Production Viper/Ilmor engines are scheduled for delivery next month. We continue to be excited about our partnership with Viper Motorcycles and look forward to a long and successful relationship." Viper Powersports designs, manufactures and markets a line of premium American V-Twin Super Cruiser motorcycles, V-Twin aftermarket engines and other related aftermarket products through an independent dealer network. A joint venture partnership with Ilmor Engineering (www.ilmor.com) provides design, technical development and support for the proprietary 152 cubic inch Viper V-Twin engine, utilizing their 25 years of high-performance engine expertise, ensuring Vipers' long term success as America's newest domestic OEM of motorcycles. Viper Powersports and Viper Motorcycle Company's websites are www.viperpowersports.com and www.vipermotorcycle.com.
------------------------------------------------------------------------------------------------------------------------------------------------------------
About StockHunter.us
StockHunter.us is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockHunter.us. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.
((Comments on this story may be sent to info@m2.com))
(c) 2010 M2 COMMUNICATIONS
[ Back To HealthTechZone.com's Homepage ]
|